<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=2653956&amp;fmt=gif">
Image Overlay - Real-world Performance of Kymriah Matches Clinical Trials
Image Overlay - Real-world Performance of Kymriah Matches Clinical Trials

Real-world Performance of Kymriah Matches Clinical Trials

Real-world Performance of Kymriah Matches Clinical Trials

Novartis made headlines when it won FDA approval for Kymriah, the first CAR-T cell therapy to reach the market. Last week, two years after it was commercialized, the company presented post-marketing data showing that its efficacy is consistent with what was shown in clinical trials, and the safety profile appears even better, according to Novartis's presentation at the annual American Society of Hematology (ASH) annual conference. With the wave of CAR-T and other cell therapies being investigated in clinical trials, Yourway has invested in its temperature-controlled logistics capabilities to support the special requirements of these trials.

Back to Index
Stay Connected

Want to stay informed about the latest news, updates, and opportunities at Yourway?

Join our newsletter mailing list to never miss an update!

Media

Upcoming Events

Precision in Pharma Supply Chain Summit Boston

November 16-17, 2026
Boston, MA

SCOPE Supply Chain & Logistics Leadership Summit

March 1-4, 2027
Orlando, FL

Media

Articles

Promises Start Partnerships. Performance Builds Them.

Open chat
Come chat with us!
Hello! How can I help you?